Research Study 2

  • Pooya Khan Mohammad Beigi


Alopecia areata is a relatively common dermatitis with 0.1–0.2% prevalence, manifested by sudden and non-scarring hair loss. Multiple etiologies have been proposed for this disease. Among which the theory of its autoimmune nature and genetic/environmental factors has been highlighted. Currently there is no certain cure for alopecia areata. Numerous treatments have been proposed, but all of them are partially effective and none of them have led to complete improvement. One of the most popular treatments is the application of local allergens which by inducing contact allergic dermatitis stimulates hair growth. One of these allergens is diphencyprone which induces an allergic response in 98–99% of patients, and its effectiveness was reported between 4% and 85%. However, for severe cases it is more effective than other proposed methods.


Alopecia areata Autoimmune Local allergens Diphencyprone Nail changes Thyroid disorders 


  1. 1.
    Wasserman D, Guzman-Sanchez DA, Scott K, McMichael A. Alopecia areata. Int J Dermatol. 2007;46(2):121–31.CrossRefPubMedGoogle Scholar
  2. 2.
    Freyschmidt-Paul P, Hoffmann R, Levine E, Sundberg JP, Happle R, McElwee KJ. Current and potential agents for the treatment of alopecia areata. Curr Pharm Des. 2001;7(3):213–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Avgerinou G, Gregoriou S, Rigopoulos D, Stratigos A, Kalogeromitros D, Katsambas A. Alopecia areata: topical immunotherapy treatment with diphencyprone. J Eur Acad Dermatol Venereol. 2008;22(3):320–3. Epub 2007 Nov 12CrossRefPubMedGoogle Scholar
  4. 4.
    McMichael AJ, Henderson RL Jr. Topical sensitizers in alopecia areata. Dermatol Nurs. 2004;16(4):333–6.PubMedGoogle Scholar
  5. 5.
    Tan E, Tay Y-K, Goh C-L, et al. The pattern of alopecia areata in Singapore – a study of 219 Asians. Int J Dermatol. 2002;41:748–53.CrossRefPubMedGoogle Scholar
  6. 6.
    Plumbe S. A practical treatise on the diseases of the skin. 4th ed. London: Printed for Sherwood, Gilber and Piper. p. 1837.Google Scholar
  7. 7.
    Bowen J. Two epidemics of alopecia areata in an asylum for girls. J Cutan General-Uri Dis. 1899;17:399–404.Google Scholar
  8. 8.
    Davis H. Epidemic alopecia areata. Br J Dermatol. 1914;26:204–10.Google Scholar
  9. 9.
    Stankler L. Synchronous alopecia in 2 siblings: a possible viral aetiology. Lancet. 1979;1:1303–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Tosti A, La Placa M, Placucci F, et al. No correlation between CMV and alopecia areata. J Invest Dermatol. 1996;107:443.CrossRefPubMedGoogle Scholar
  11. 11.
    Yang S, Yang J, Liu JB, et al. The genetic epidemiology of alopecia areata in China. Br J Dermatol. 2004;151:16–23.CrossRefPubMedGoogle Scholar
  12. 12.
    McMichael AJ. The genetic epidemiol autoimmune pathogenesis alopecia areata. J Eur Acad Dermatol Venereol. 1997;9:36–43.CrossRefGoogle Scholar
  13. 13.
    Xiao FL, Zhou FS, Liu JB, et al. Association of HLA-DQA1 and DQB1 alleles with alolpecia areata in Chinese Hans. Arch Dermatol Res. 2005;297:201–9.CrossRefPubMedGoogle Scholar
  14. 14.
    McDonagh AJ, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol. 2002;27:405–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Ross EK, Shapiro J. Management of hair loss. Dermatol Clin. 2005;23:227–43.CrossRefPubMedGoogle Scholar
  16. 16.
    Porter D, Burton JL. A comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. Br J Dermatol. 1971;85:272–3.CrossRefPubMedGoogle Scholar
  17. 17.
    Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis, efficacy side effects including histologic study ensuing localized acneiform response. Dermatologica. 1970;141:193–202.CrossRefPubMedGoogle Scholar
  18. 18.
    Tosti A, Piraccini BM, Pazzaglia M, et al. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003;49:96–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol. 1992;128:1467–73.CrossRefPubMedGoogle Scholar
  20. 20.
    Buhl AE. Minoxidil’s action in hair follicles. J Invest Dermatol. 1991;96:73S–4S.CrossRefPubMedGoogle Scholar
  21. 21.
    Vanderveen EE, Ellis CN, Kang S, et al. Topical minoxidil for hair regrowth. J Am Acad Dermatol. 1984;11:416–21.CrossRefPubMedGoogle Scholar
  22. 22.
    Fiedler-Weiss VC, Buys CM. Response to minoxidil in severe alopecia areata correlates with T lymphocyte stimulation. Br J Dermatol. 1987;117:759–63.CrossRefPubMedGoogle Scholar
  23. 23.
    Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol. 1987;16:730–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Ranchoff RE, Bergfeld WF, Steck WD, et al. Extensive alopecia areata. Results of treatment with 3% top minoxidil. Cleve Clin J Med. 1989;56:149–54.CrossRefPubMedGoogle Scholar
  25. 25.
    Fiedler-Weiss VC, Buys CM. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol. 1987;123:1491–3.CrossRefPubMedGoogle Scholar
  26. 26.
    Schmoeckel C, Weissmann I, Plewig G, et al. Treatment of alopecia areata by anthralin-induced dermatitis. Arch Dermatol. 1979;115:1254–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Lassus A, Kianto U, Johansson E, et al. PUVA treatment for alopecia areata. Dermatologica. 1980;161:298–304.CrossRefPubMedGoogle Scholar
  28. 28.
    Claudy AL, Gagnaire D. PUVA treatment alopecia areata. Arch Dermatol. 1983;119:975–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Healy E, Rogers S. PUVA treatment for alopecia areata – does it work? A retrospective review of 102 cases. Br J Dermatol. 1993;129:42–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Behrens-Williams SC, Leiter U, Schiener R, et al. The PUVA-turban as a new option of applying a dilute psoralen solution selectively to the scalp of patients with alopecia areata. J Am Acad Dermatol. 2001;44:248–52.CrossRefPubMedGoogle Scholar
  31. 31.
    Whitmont K, Cooper A. PUVA treatment of alopecia areata totalis and universalis: a retrospective study. Australas J Dermatol. 2003;44:106–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Van der Schaar WW, Sillevis Smith JH. An evaluation of PUVA-therapy for alopecia areata. Dermatologica. 1984;168:250–2.CrossRefPubMedGoogle Scholar
  33. 33.
    Ferrando J, Grimalt R. Partial response of severe alopecia areata to cyclosporine A. Dermatology. 1999;199:67–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Paquet P, Arrese EJ, Pierard GE. Oral cyclosporin alopecia areata. Dermatology. 1992;185:314–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Shapiro J, Lui H, Tron V, et al. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation. J Am Acad Dermatol. 1997;36:114–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Yamamoto S, Jiang H, Kato R. Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent. J Invest Dermatol. 1994;102:160–4.CrossRefPubMedGoogle Scholar
  37. 37.
    McMichael AJ. The new biologics in psoriasis: possible treatments for alopecia areata. J Invest Dermatol Symp Proc. 2003;8:217–8.CrossRefGoogle Scholar
  38. 38.
    Strober B, Siu K, Alexis A, et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol. 2005;52:1082–4.CrossRefPubMedGoogle Scholar
  39. 39.
    Posten W, Swan J. Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol. 2005;141:759–60.CrossRefPubMedGoogle Scholar
  40. 40.
    Ettefagh L, Neodorost S, Mirmirani P. Alopecia areta in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. Arch Dermatol. 2004;140:1012.CrossRefPubMedGoogle Scholar
  41. 41.
    Kratka J, Goerz G, Vizethum W, et al. Dinitrochlorobenzene: influence on the cytochrome P-450 system and mutagenic effects. Arch Dermatol Res. 1979;266:315–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Strobel R, Rohrborn G. Mutagenic cell transforming activities 1-chlor-2,4-dinitrobenzene (DNCB) squaric- acid-dibutylester (SADBE). Arch Toxicol. 1980;45:307–14.CrossRefPubMedGoogle Scholar
  43. 43.
    Wilkerson MG, Henkin J, Wilkin JK, et al. Squaric acid and esters: analysis for contaminants and stability in solvents. J Am Acad Dermatol. 1985;13:229–34.CrossRefPubMedGoogle Scholar
  44. 44.
    Breslow BM, Haynie R, Mirra J. Synthesis of diphencyclopropenone. J Am Chem Soc. 1959;81:247–8.CrossRefGoogle Scholar
  45. 45.
    Van der Steen PH, Happle R. Top immunotherapy alopecia areata. Dermatol Clin. 1993;11:619–22.PubMedCrossRefGoogle Scholar
  46. 46.
    Shapiro J, Tan J, Ho V, et al. Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation. J Am Acad Dermatol. 1993;29:729–35.CrossRefPubMedGoogle Scholar
  47. 47.
    Hull SM, Pepall L, Cunliffe WJ. Alopecia areata in children: response to treatment with diphencyprone. Br J Dermatol. 1991;125:164–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Cotellessa C, Peris K, Caracciolo E, et al. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol. 2001;44:73–6.CrossRefPubMedGoogle Scholar
  49. 49.
    Hoffmann R, Happle R. Topical immunotherapy in alopecia areata. What, how, and why? Dermatol Clin. 1996;14(4):739–44.CrossRefPubMedGoogle Scholar
  50. 50.
    Perret CM, Steijlen PM, Zaun H, Happle R. Erythema multiforme-like eruptions: a rare side effect of topical immunotherapy with diphenylcyclopropenone. Dermatologica. 1990;180(1):5–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Sotiriadis D, Patsatsi A, Lazaridou E, Kastanis A, Vakirlis E, Chrysomallis F. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata. Clin Exp Dermatol. 2007;32(l):48–51.PubMedGoogle Scholar
  52. 52.
    MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG. Guidelines for the management of alopecia areata. Br J Dermatol. 2003;149:692–9.CrossRefPubMedGoogle Scholar
  53. 53.
    D. A Buckley/ A.W.P Du vivier. The therapeutic use of topical contact sensitizers in benign dermatoses. Br J Dermatol 2001;145:385–405.CrossRefPubMedGoogle Scholar
  54. 54.
    Pazoki-Toroudi H, Ajami M, Babakoohi S, Khaki L, Habibey R, Akhiani M, Seirafi H, Firooz A. Effects of diphencyprone on expression of Bcl-2 protein in patients with alopecia areata. Immunopharmacol Immunotoxicol. 2010;32(3):422–5.CrossRefPubMedGoogle Scholar
  55. 55.
    Seyrafi H, Akhiani M, Abbasi H, Mirpour S, Gholamrezanezhad A. Valuation of the profile of alopecia areata and the prevalence of thyroid function test abnormalities and serum autoantibodies in Iranian patients. BMC Dermatol. 2005;5:11.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part II Treatment. J Am Acad Dermatol. 2010;62(2):191–202. quiz 203–4. ReviewCrossRefPubMedGoogle Scholar
  57. 57.
    Gregoriou S, Papafragkaki D, Kontochristopoulos G, Rallis E, Kalogeromitros D, Rigopoulos D. Cytokines and other mediators in alopecia areata. Mediat Inflamm. 2010;2010:928030. Epub 2010 Mar 11. ReviewCrossRefGoogle Scholar
  58. 58.
    Aghaei S. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population. BMC Dermatol. 2005;5:6.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Tobin DJ, Gardner SH, Lindsey NJ, Hoffmann R, Happle R, Freyschmidt-Paul P. Diphencyprone immunotherapy alters anti-hair follicle antibody status in patients with alopecia areata. Eur J Dermatol. 2002;12(4):327–34.PubMedGoogle Scholar
  60. 60.
    Aandt K, Robinson J, LeBoit P, Wintroub B. Cutaneus medicine and surgery: an integrated program in dermatology, 1996, W.B Souders company, p. 174–195.Google Scholar
  61. 61.
    Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A. Leffell D. Fitzpatrick’s dermatology in general medicine. 7th ed. New York: Mc Graw Hill; 2008. p. 137.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Pooya Khan Mohammad Beigi
    • 1
    • 2
    • 3
  1. 1.Department of Health ManagementNew York Medical CollegeValhallaUSA
  2. 2.University of British ColumbiaVancouverCanada
  3. 3.Misdiagnosis AssociationSeattleUSA

Personalised recommendations